X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Newspaper Article (545) 545
Journal Article (517) 517
Book Chapter (142) 142
Book Review (9) 9
Book / eBook (8) 8
Magazine Article (5) 5
Dissertation (3) 3
Patent (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (315) 315
life sciences & biomedicine (287) 287
humans (242) 242
female (154) 154
male (131) 131
abridged index medicus (103) 103
aged (101) 101
middle aged (92) 92
cardiovascular system & cardiology (84) 84
risk factors (67) 67
rivaroxaban (65) 65
cardiac & cardiovascular systems (61) 61
treatment outcome (54) 54
adult (53) 53
anticoagulants (51) 51
atrial fibrillation (46) 46
stroke (45) 45
analysis (43) 43
peripheral vascular disease (41) 41
cell biology (38) 38
prevention (38) 38
double-blind method (37) 37
animals (34) 34
warfarin (33) 33
care and treatment (32) 32
general & internal medicine (32) 32
hemorrhage - chemically induced (31) 31
medicine, general & internal (31) 31
stroke - prevention & control (31) 31
anticoagulants - therapeutic use (30) 30
research (30) 30
drug therapy (29) 29
biochemistry & molecular biology (28) 28
neurosciences & neurology (28) 28
anticoagulants - adverse effects (27) 27
clinical trials (27) 27
studies (27) 27
patients (26) 26
physical sciences (26) 26
united states (26) 26
aged, 80 and over (25) 25
atrial fibrillation - drug therapy (25) 25
social sciences (25) 25
anticoagulants - administration & dosage (23) 23
surgery (23) 23
thromboembolism (22) 22
atrial fibrillation - complications (21) 21
dosage and administration (21) 21
health aspects (21) 21
pediatrics (21) 21
time factors (21) 21
adolescent (20) 20
warfarin - therapeutic use (20) 20
administration, oral (19) 19
cardiac arrhythmia (19) 19
comparative analysis (19) 19
heart attacks (19) 19
stroke - etiology (19) 19
warfarin - administration & dosage (19) 19
aspirin (18) 18
bleeding (18) 18
cancer (18) 18
clinical neurology (18) 18
hemorrhage (18) 18
retrospective studies (18) 18
warfarin - adverse effects (18) 18
child (17) 17
factor xa inhibitors - administration & dosage (17) 17
follow-up studies (17) 17
oncology (17) 17
rivaroxaban - administration & dosage (17) 17
thrombosis (17) 17
cancer genome atlas research network (16) 16
hematology (16) 16
medical colleges (16) 16
medicine (16) 16
pregnancy (16) 16
settore med/27 - neurochirurgia (16) 16
cardiovascular (15) 15
complications and side effects (15) 15
dose-response relationship, drug (15) 15
internal medicine (15) 15
morpholines - adverse effects (15) 15
morpholines - therapeutic use (15) 15
neoplasms - genetics (15) 15
thiophenes - adverse effects (15) 15
biochemistry, genetics and molecular biology (14) 14
embolism - prevention & control (14) 14
factor xa inhibitors - adverse effects (14) 14
incidence (14) 14
magnetic resonance imaging (14) 14
mortality (14) 14
mutation (14) 14
prospective studies (14) 14
public, environmental & occupational health (14) 14
thiophenes - therapeutic use (14) 14
vitamin k - antagonists & inhibitors (14) 14
610 medicine & health (13) 13
blood pressure (13) 13
body mass index (13) 13
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Faculty of Information - Stacks (1) 1
Gerstein Science - Stacks (1) 1
OISE - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
UTL at Downsview - May be requested (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2009, Volume 373, Issue 9676, pp. 1673 - 1680
Summary Background Prophylaxis for venous thromboembolism is recommended for at least 10 days after total knee arthroplasty; oral regimens could enable shorter... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Arthroplasty, Replacement, Knee - adverse effects | Follow-Up Studies | Thiophenes - adverse effects | Humans | Middle Aged | Venous Thrombosis - diagnostic imaging | Male | Enoxaparin - therapeutic use | Incidence | Rivaroxaban | Sensitivity and Specificity | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Risk Reduction Behavior | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Venous Thrombosis - etiology | Phlebography | Analysis of Variance | Venous Thrombosis - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Enoxaparin | Anticoagulants (Medicine) | Dosage and administration | Thrombophlebitis | Comparative analysis | Risk factors | Studies | Blood transfusions | Sensitivity analysis | Medical imaging | Hospitals | Protease inhibitors | Surgery | Joint surgery | Drug therapy | Thrombosis | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Knee | Venous Thrombosis | Oral | Hemorrhage | epidemiology | Thiophenes | Administration | Anticoagulants | chemically induced | Arthroplasty | Replacement | prevention & control | radiography | Morpholines | Kirurgi | etiology | adverse effects | therapeutic use
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2018, Volume 378, Issue 23, pp. 2191 - 2201
In a randomized trial involving patients who had a first stroke from an embolus of unknown source, rivaroxaban at a daily dose of 15 mg did not result in a... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Stroke - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Brain Ischemia - prevention & control | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Intracranial Embolism - drug therapy | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke (Disease) | Prevention | Rivaroxaban | Complications and side effects | Dosage and administration | Drug therapy | Hemorrhage | Risk factors | Cardiac arrhythmia | Neurosciences | Embolisms | Stenosis | Bleeding | Design | Ischemia | Atherosclerosis | Drug dosages | Research centers | Anticoagulants | Medical research | Stroke | Aspirin | Internal medicine | Research & development--R&D | Thrombosis | Patients | Embolism | Blood clots | Medicine | Neurology | Hospitals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | metaanalysis | atrial-fibrillation | foramen ovale closure | antithrombotic therapy | Klinisk medicin | efficacy | warfarin | Clinical Medicine | trials | safety | design | cryptogenic stroke
Journal Article
The American heart journal, ISSN 0002-8703, 06/2015, Volume 169, Issue 6, pp. 751 - 757
Journal Article
The American heart journal, ISSN 0002-8703, 10/2015, Volume 170, Issue 4, pp. 675 - 682.e8
Journal Article
The American journal of cardiology, ISSN 0002-9149, 06/2017, Volume 119, Issue 12, pp. 1989 - 1996
Journal Article
The American heart journal, ISSN 0002-8703, 09/2016, Volume 179, pp. 77 - 86
Journal Article